Arch Biopartners (TSXV:ARCH) Debt-to-Equity : -0.88 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Debt-to-Equity?

Arch Biopartners's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$4.54 Mil. Arch Biopartners's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.50 Mil. Arch Biopartners's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$-5.71 Mil. Arch Biopartners's debt to equity for the quarter that ended in Dec. 2023 was -0.88.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Arch Biopartners's Debt-to-Equity or its related term are showing as below:

TSXV:ARCH' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.09 Med: -0.98 Max: 83.25
Current: -0.88

During the past 13 years, the highest Debt-to-Equity Ratio of Arch Biopartners was 83.25. The lowest was -7.09. And the median was -0.98.

TSXV:ARCH's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs TSXV:ARCH: -0.88

Arch Biopartners Debt-to-Equity Historical Data

The historical data trend for Arch Biopartners's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Debt-to-Equity Chart

Arch Biopartners Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Equity

Get a 7-Day Free Trial

-1.09

-0.88

-1.33

-0.99

-0.91

Arch Biopartners Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-0.98	-1.09	-0.87	-0.91	-0.88

Competitive Comparison of Arch Biopartners's Debt-to-Equity

For the Biotechnology subindustry, Arch Biopartners's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Biopartners's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Debt-to-Equity falls into.

Arch Biopartners Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Arch Biopartners's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.312	+	0.704)	/	-5.51
	=	-0.91

Arch Biopartners's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.537	+	0.5)	/	-5.713
	=	-0.88

Arch Biopartners (TSXV:ARCH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Arch Biopartners Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners (TSXV:ARCH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.